Nirvana Life Sciences Inc. NIRVX
CNSX
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -40.10% | 72.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.10% | 72.46% | |||
| Operating Income | 40.10% | -72.46% | |||
| Income Before Tax | 41.07% | -147.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.07% | -147.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.37% | -147.17% | |||
| EBIT | 40.10% | -72.46% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 41.38% | -141.67% | |||
| Normalized Basic EPS | 44.44% | -80.00% | |||
| EPS Diluted | 41.38% | -141.67% | |||
| Normalized Diluted EPS | 44.44% | -80.00% | |||
| Average Basic Shares Outstanding | -0.48% | 0.48% | |||
| Average Diluted Shares Outstanding | -0.48% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||